News

Feature: Tasman redefining treatment for hard-to-treat depression with breakthrough oral ketamine monotherapy

April 29, 2025 at 12:00:00 AM

BioTuesdays looks into R-107

By Melane Sampson

Closely held Tasman Therapeutics is shifting the treatment landscape for treatment-resistant depression (TRD) with its registered, proprietary formulation—a first-of-its-kind, oral extended-release ketamine tablet.

See the full story here: Tasman redefining treatment for hard-to-treat depression with breakthrough oral ketamine monotherapy - BioTuesdays